Default company panoramic image
7e9646d8 d54b 405c 9744 a9d9e60aef02

OcuCure Therapeutics

We are a clinical stage ophthalmic pharmaceutical company developing a topical eye drop to treat both Age-related Macular Degeneration and Diabetic Retinopathy.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Roanoke, VA, US
  • Currency USD
  • Founded December 2005
  • Website ocucure.com

Company Summary

OcuCure Therapeutics is a clinical stage ophthalmic pharma company developing a proprietary topical eye drop to treat both Age-related Macular Degeneration (AMD) and Diabetic Retinopathy (DR). Currently available AMD drugs are administered by injection into the eye and there are no drugs approved to treat DR. The eye drop has demonstrated safety in a proof of concept human clinical trial and a proof of concept efficacy trial has been initiated.

Team

  • 1abae2be 9a4d 4ad2 afd7 9646c99a4e4b
    VP Pharmaceutical Services

    Extensive experience with biomedical startup companies and extremely knowledgeable about university tech transfer processes and in-licensing from academic institutions. Sam has licensed 10 technologies from university partners. While at Carilion, Sam was responsible for managing the research that led to the discovery of the OcuCure small antiangiogenic molecules.

  • Default avatar
    Craig Greven, M.D., FACS
    Consulting Chief Medical Officer

    Dr. Greven is the Richard Weaver Professor and Chair of the Ophthalmology Dept. at Wake Forest University School of Medicine. He is a member of the American Society of Retinal Specialists, the Retina Society, and the Macula Society. He has been PI on multiple AMD and DR clinical trials and published/spoken internationally on retinal diseases. He has received the Honor Award and Senior Achievement Award from the American Academy of Ophthalmology.

  • 09c1a042 da8c 4229 9e43 eeb062c61d83
    President, CEO & Director

    Sunder has over 35 years of experience in creating and growing new businesses in the eye care space. He has been a senior executive of major multinational companies and in start-up ventures. Sunder developed and commercialized the AOSEPT contact lens solution which was acquired by Novartis. He was a member of the Innotech executive team, a venture funded start-up company that went public on the NASDAQ and was acquired by Johnson & Johnson.

  • Default avatar
    Pat Williams, Ph.D.
    Chief Scientific Officer

    Pat has over 30 years of experience in both preclinical and clinical pharmacology. She focuses on safe and efficacious treatments for blinding eye diseases. Pat is a founding member of EyeRx Research, Inc., where she has teamed with ophthalmologists and other scientists to develop several ophthalmic drugs through to clinical trials and the FDA regulatory process. Pat’s team has been awarded 7 patents.